Recruiting
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
NCT06465199· Phase 1/2· Milton S. Hershey Medical Center· Source
Contact: Gina Martin
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Recruiting
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
NCT06540963· Phase 2· Giselle Sholler· Source
Contact: Gina Martin
Recruiting
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
NCT06541262· Phase 1/2· Milton S. Hershey Medical Center· Source
Contact: Gina Martin
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· Phase 2· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: William S. Ferguson (principal investigator)
Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338· Phase 3· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585· Phase 3· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Children's Oncology Group· Source
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· Phase 1/2· PedAL BCU, LLC· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer
NCT05228275· Children's Oncology Group· Source
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· Phase 3· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· Phase 3· Children's Oncology Group· Source
Recruiting
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368· Phase 2· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029· Phase 2· Giselle Sholler· Source
Contact: Gina Martin
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· Phase 2· National Cancer Institute (NCI)· Source
Contact: William S. Ferguson (principal investigator)
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· Phase 2· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409· Phase 3· National Cancer Institute (NCI)· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· Phase 3· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Active, not recruiting
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
NCT03834961· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
NCT03581292· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03210714· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03213704· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
NCT03057626· Children's Oncology Group· Source
Active, not recruiting
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Neuroblastoma Maintenance Therapy Trial
NCT02679144· Phase 2· Giselle Sholler· Source
Recruiting
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Source
Contact: William S. Ferguson (principal investigator)
Recruiting
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778· Phase 2· Giselle Sholler· Source
Contact: Gina Martin, RN
Active, not recruiting
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306161· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967· Phase 3· Children's Oncology Group· Source
Showing 50 of 52.